Moreover, we investigated the effects of rapamycin on other leukemia models established by transduction of the AML1 mutant (AML1_S291fsX300) [55] and coexpression of TEL/PDGFβR and AML1/ETO [56] and found no changes in their survival; this demonstrated the specific sensitivity of Evi1-activated leukemia cells to rapamycin (Figure 1). This evidence concerns the gene RUNX1 and leukemia.